ClinicalTrials.gg
CompletedNCT00138749Updated Apr 7, 2011

An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence.

A Phase 2 interventional study of SS-RBX in Urinary Incontinence, Stress, sponsored by Pfizer. Completed at 95 sites in 2 countries. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-04-07.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
402
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 189 studies in Urinary Incontinence, Stress with a site in United States — 27 open to participants now, 40 under way, 3 of them phase 3. Urinary Incontinence, Stress · United States.

Enrollment
18th of 163
402 · median 98
Started
2004
with 6 others
Phase 2
12 of 189
1 open now
Registered
5th of 189
by date

Among the 189 studies in Urinary Incontinence, Stress with a site in United States, this one is the 18th largest by enrollment of the 163 interventional ones that give a count, is one of 7 that started in 2004, is one of 12 in phase 2, and was the 5th registered.

Urinary Incontinence, Stress

653 studies on the registry are indexed under Urinary Incontinence, Stress; 122 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

27 of the 189 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Urinary Incontinence, Stress studies recruiting now, 42 (56%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 189 studies in Urinary Incontinence, Stress with a site in United States, or all of them as a file.
02

Study summary

A study designed to assess the efficacy, toleration and safety of SS-RBX for the treatment of stress urinary incontinence.

03

Conditions studied

  • Urinary Incontinence, Stress
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • stress urinary incontinence

Exclusion criteria

Exclusion Criteria:

  • History or evidence of any relevant confounding urological or neurological disease
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
402 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Proof of concept study to assess the efficacy, tolerability and safety of SS-RBX vs. placebo in the treatment of SUI.

Secondary outcomes

  1. To evaluate whether an upward dose adjustment affects the tolerability of SS-RBX.

07

Study locations

95 sites
  • Pfizer Investigational Site
    Anchorage, Alaska 99508, United States
  • Pfizer Investigational Site
    Sun City, Arizona 85351, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85712-5803, United States
  • Pfizer Investigational Site
    Tucson, Arizona 85712, United States
  • Pfizer Investigational Site
    Little Rock, Arkansas 72205, United States
  • Pfizer Investigational Site
    Atherton, California 94027, United States
  • Pfizer Investigational Site
    Carmichael, California 95608, United States
  • Pfizer Investigational Site
    Laguna Woods, California 92653, United States
  • Pfizer Investigational Site
    Murrieta, California 92562, United States
  • Pfizer Investigational Site
    Newport Beach, California 92660, United States
  • Pfizer Investigational Site
    Sacramento, California 95825, United States
  • Pfizer Investigational Site
    San Diego, California 92103, United States
  • Pfizer Investigational Site
    Tarzana, California 91356, United States
  • Pfizer Investigational Site
    Temecula, California 92591, United States
  • Pfizer Investigational Site
    Torrance, California 90505, United States
  • Pfizer Investigational Site
    Vista, California 92084, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80012, United States
  • Pfizer Investigational Site
    Denver, Colorado 80210, United States
  • Pfizer Investigational Site
    Denver, Colorado 80220, United States
  • Pfizer Investigational Site
    Wheat Ridge, Colorado 80033, United States
  • Pfizer Investigational Site
    New London, Connecticut 06320, United States
  • Pfizer Investigational Site
    Waterbury, Connecticut 06708, United States
  • Pfizer Investigational Site
    Aventura, Florida 33180, United States
  • Pfizer Investigational Site
    New Port Richey, Florida 34652, United States
  • Pfizer Investigational Site
    Panama City, Florida 32405, United States
  • Pfizer Investigational Site
    Panama City, Florida 32407, United States
  • Pfizer Investigational Site
    Pembroke Pines, Florida 33028, United States
  • Pfizer Investigational Site
    Port Richey, Florida 34668, United States
  • Pfizer Investigational Site
    West Palm Beach, Florida 33407, United States
  • Pfizer Investigational Site
    Alpharetta, Georgia 30005, United States
  • Pfizer Investigational Site
    Coeur D Alene, Idaho 83814, United States
  • Pfizer Investigational Site
    Arlington Heights, Illinois 60004, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60616, United States
  • Pfizer Investigational Site
    Melrose Park, Illinois 60160, United States
  • Pfizer Investigational Site
    Greenwood, Indiana 46143, United States
  • Pfizer Investigational Site
    Indianapolis, Indiana 46202, United States
  • Pfizer Investigational Site
    Des Moines, Iowa 50309, United States
  • Pfizer Investigational Site
    Louisville, Kentucky 40291, United States
  • Pfizer Investigational Site
    Shreveport, Louisiana 71106, United States
  • Pfizer Investigational Site
    Greenbelt, Maryland 20770, United States
  • Pfizer Investigational Site
    Watertown, Massachusetts 02472, United States
  • Pfizer Investigational Site
    Jackson, Mississippi 39202, United States
  • Pfizer Investigational Site
    Jackson, Mississippi 39216, United States
  • Pfizer Investigational Site
    Liberty, Missouri 64068, United States
  • Pfizer Investigational Site
    North Kansas City, Missouri 64116, United States
  • Pfizer Investigational Site
    Omaha, Nebraska 68114, United States
  • Pfizer Investigational Site
    Henderson, Nevada 89014, United States
  • Pfizer Investigational Site
    Edison, New Jersey 08837, United States
  • Pfizer Investigational Site
    West Orange, New Jersey 07052, United States
  • Pfizer Investigational Site
    Albuquerque, New Mexico 87108, United States
  • Pfizer Investigational Site
    Albany, New York 12208, United States
  • Pfizer Investigational Site
    Garden City, New York 11530-1630, United States
  • Pfizer Investigational Site
    Garden City, New York 11530, United States
  • Pfizer Investigational Site
    Mineola, New York 11501, United States
  • Pfizer Investigational Site
    Poughkeepsie, New York 12601, United States
  • Pfizer Investigational Site
    Burlington, North Carolina 27215, United States
  • Pfizer Investigational Site
    Charlotte, North Carolina 28204, United States
  • Pfizer Investigational Site
    Concord, North Carolina 28025, United States
  • Pfizer Investigational Site
    Fayetteville, North Carolina 28304, United States
  • Pfizer Investigational Site
    Winston-salem, North Carolina 27103, United States
  • Pfizer Investigational Site
    Cincinnati, Ohio 45212, United States
  • Pfizer Investigational Site
    Bethany, Oklahoma 73008, United States
  • Pfizer Investigational Site
    Eugene, Oregon 97401-2676, United States
  • Pfizer Investigational Site
    Eugene, Oregon 97401, United States
  • Pfizer Investigational Site
    Medford, Oregon 97504, United States
  • Pfizer Investigational Site
    Portland, Oregon 97239, United States
  • Pfizer Investigational Site
    Colmar, Pennsylvania 18915, United States
  • Pfizer Investigational Site
    Lancaster, Pennsylvania 17604, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19114, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Pfizer Investigational Site
    Sellersville, Pennsylvania 18960, United States
  • Pfizer Investigational Site
    Sewickley, Pennsylvania 15143, United States
  • Pfizer Investigational Site
    Providence, Rhode Island 02904, United States
  • Pfizer Investigational Site
    Charleston, South Carolina 29425, United States
  • Pfizer Investigational Site
    Columbia, South Carolina 29201, United States
  • Pfizer Investigational Site
    Greer, South Carolina 29651, United States
  • Pfizer Investigational Site
    Myrtle Beach, South Carolina 29572, United States
  • Pfizer Investigational Site
    Knoxville, Tennessee 37920-1522, United States
  • Pfizer Investigational Site
    Knoxville, Tennessee 37920, United States
  • Pfizer Investigational Site
    Corpus Christi, Texas 78414, United States
  • Pfizer Investigational Site
    Corsicana, Texas 75110, United States
  • Pfizer Investigational Site
    Houston, Texas 77024, United States
  • Pfizer Investigational Site
    San Antonio, Texas 78229, United States
  • Pfizer Investigational Site
    Salt Lake City, Utah 84132, United States
  • Pfizer Investigational Site
    Sandy, Utah 84070, United States
  • Pfizer Investigational Site
    Sandy, Utah 84094, United States
  • Pfizer Investigational Site
    West Jordan, Utah 84088, United States
  • Pfizer Investigational Site
    Virginia Beach, Virginia 23454, United States
  • Pfizer Investigational Site
    Seattle, Washington 98104, United States
  • Pfizer Investigational Site
    Surrey, British Columbia V3V-1N1, Canada
  • Pfizer Investigational Site
    Victoria, British Columbia V8T5G1, Canada
  • Pfizer Investigational Site
    Kitchener, Ontario N2M 5N4, Canada
  • Pfizer Investigational Site
    Oakville, Ontario L6H 3P1, Canada
  • Pfizer Investigational Site
    Montreal, Quebec H3S 1Z1, Canada
  • Pfizer Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2004, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2005
First posted
Aug 30, 2005
Start
Nov 2004
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Last update
Apr 7, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00138749
Lead sponsor
Pfizer
First posted
Aug 30, 2005
Start date
Nov 2004
Primary completion
Aug 2006
Completion
Aug 2006
Last update
Apr 7, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esreboxetine

Start the discussion